Literature DB >> 15170497

Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study.

F Giorgino1, L Laviola, P Cavallo Perin, B Solnica, J Fuller, N Chaturvedi.   

Abstract

AIMS/HYPOTHESIS: Type 1 diabetic patients who develop microalbuminuria are clearly disadvantaged in terms of their risk of morbidity and mortality from renal and cardiovascular diseases. It is therefore important to identify potential factors that can predict progression to macroalbuminuria.
METHODS: This is a 7-year follow-up study of 352 microalbuminuric Type 1 diabetic patients from 31 European centres. Risk factors at baseline were compared in patients who progressed to macroalbuminuria and in patients who remained microalbuminuric or reverted to normoalbuminuria. Risk factors and albumin excretion rate (AER) were measured centrally.
RESULTS: Over 7.3 years, 13.9% of the microalbuminuric patients progressed to macroalbuminuria, 35.5% remained microalbuminuric and 50.6% reverted to normoalbuminuria. Independent baseline risk factors for progression to macroalbuminuria were HbA(1)c (7.9% vs 6.8%, p=0.004), AER (64.4 vs 44.9 microg/min, p=0.0001) and-after adjusting for diabetes duration, HbA(1)c and AER-body weight (72 vs 67 kg, p=0.05). Independent factors associated with regression to normoalbuminuria were diabetes duration (15 vs 18 years, p=0.004), AER (37.2 vs 44.9 microg/min, p=0.0001) and-after adjusting for diabetes duration, HbA(1)c and AER-waist-to-hip ratio (0.83 vs 0.86, p=0.05) and incidence of peripheral neuropathy at baseline (24% vs 38%, p=0.001). Blood pressure and smoking did not emerge as risk factors at baseline for the outcome of microalbuminuria. CONCLUSIONS/
INTERPRETATION: A significant fraction of microalbuminuric Type 1 diabetic patients will progress to overt proteinuria. Patients with higher AER values, sub-optimal metabolic control, excess body fat and peripheral neuropathy may carry a particularly high risk of clinical nephropathy requiring aggressive therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170497     DOI: 10.1007/s00125-004-1413-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  44 in total

1.  A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

Authors:  G R Warnick; J J Albers
Journal:  J Lipid Res       Date:  1978-01       Impact factor: 5.922

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

4.  Enzyme immunoassay--a new technique for estimating hemoglobin A1c.

Authors:  W G John; M R Gray; D L Bates; J L Beacham
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

5.  Smoking and progression of diabetic nephropathy in type 1 diabetes.

Authors:  Peter Hovind; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

6.  Insulin resistance in insulin-dependent diabetic patients with microalbuminuria.

Authors:  J Yip; M B Mattock; A Morocutti; M Sethi; R Trevisan; G Viberti
Journal:  Lancet       Date:  1993-10-09       Impact factor: 79.321

7.  Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.

Authors: 
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

8.  The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study.

Authors:  N Chaturvedi; J M Stephenson; J H Fuller
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

9.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

10.  Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy.

Authors:  S B Solerte; M Fioravanti; N Schifino; E Ferrari
Journal:  Int J Obes       Date:  1989
View more
  44 in total

1.  Association of APOA5 Gene Promoter Region -1131T>C Polymorphism (rs662799) to Plasma Triglyceride Level in Patients with Type 2 Diabetic Nephropathy.

Authors:  Abdolkarim Mahrooz; Mehryar Zargari; Vahid Ansari; Atieh Makhlough; Mohammad-Bagher Hashemi-Sooteh
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes.

Authors:  Shalamar D Sibley; Ian H de Boer; Michael W Steffes; John D Brunzell
Journal:  Diabetes Care       Date:  2007-04-24       Impact factor: 19.112

Review 3.  Proteomic discovery of diabetic nephropathy biomarkers.

Authors:  Michael L Merchant; Jon B Klein
Journal:  Adv Chronic Kidney Dis       Date:  2010-11       Impact factor: 3.620

Review 4.  Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics.

Authors:  Julie A D Van; James W Scholey; Ana Konvalinka
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

Review 5.  Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species.

Authors:  Catharine I Whiteside
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

6.  Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY).

Authors:  Norio Nakamura; Ikuyo Narita; Takeshi Fujita; Reiichi Murakami; Michiko Shimada; Masayuki Nakamura; Hiroshi Osawa; Hideaki Yamabe; Ken Okumura
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 7.  Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Authors:  Andrzej S Krolewski; Tomohito Gohda; Monika A Niewczas
Journal:  Clin Exp Nephrol       Date:  2013-11-12       Impact factor: 2.801

8.  Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule.

Authors:  Y Vergouwe; S S Soedamah-Muthu; J Zgibor; N Chaturvedi; C Forsblom; J K Snell-Bergeon; D M Maahs; P-H Groop; M Rewers; T J Orchard; J H Fuller; K G M Moons
Journal:  Diabetologia       Date:  2009-11-04       Impact factor: 10.122

9.  Long-term prevention of diabetic nephropathy: an audit.

Authors:  K J Schjoedt; H P Hansen; L Tarnow; P Rossing; H-H Parving
Journal:  Diabetologia       Date:  2008-04-03       Impact factor: 10.122

10.  Microalbuminuria predicts overt proteinuria among patients with HIV infection.

Authors:  L A Szczech; P Menezes; E Byrd Quinlivan; C van der Horst; J A Bartlett; L P Svetkey
Journal:  HIV Med       Date:  2010-01-04       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.